Jeffrey Sachs and Mark Pavao join Board of Advisors

Company News | March 4, 2015

Jeffrey A. Sachs is a leading health care policy expert who has worked with federal and state governments, hospitals, health systems, health plans, behavioral health organizations, technology companies, unions and others for more than three decades. Dr. Sachs is the principal of the Sachs Policy Group, a boutique consulting firm in New York City that advises health care leaders on state and federal health care policy, trends, and business strategy. Dr. Sachs was one of the architects of the recent New York State Medicaid Redesign Team process and its accompanying $8 billion Medicaid waiver. The result was one of the nation’s most innovative and comprehensive Medicaid overhauls. In 2010, Dr. Sachs provided guidance on the development of California’s 2010 Medicaid waiver which disbursed $10 billion over five years to secure the safety net and help implement national health care reform in California. Mark Pavao is a biopharma commercialization leader with strategic, operational, and P&L experience at companies that range from entrepreneurial ventures to big pharma. He has demonstrated success in a range of situations including US and global start-up, growth and turnaround environments. Mark has marketing, market access, sales leadership, and full lifecycle management expertise, ranging from development and launch to mid-life and patent expiry. Mark was the President of the US Diabetes Alliance between AstraZeneca and Bristol-Myers Squibb (BMS). From 2010-2012, Mark served as President of Emerging Markets at BMS, and SVP of Global Market Access & Pricing from 2008-2012. Before moving to global roles, Mark was SVP for the Neuroscience Business Unit and VP of Plavix Marketing, both in the US Pharmaceuticals Division at BMS. Mark started at BMS as VP of Neuroscience Marketing and led the U.S. launch of Abilify. Previously, Mark was the SVP of Sales and Marketing for NitroMed Inc. and Vice President of Sales and Marketing at Helios Health, a venture-backed healthcare information and media start-up. During his early career, Mark held progressively responsible sales, marketing, and market access positions at SmithKline Beecham.